<DOC>
	<DOC>NCT00174798</DOC>
	<brief_summary>To evaluate the safety and efficacy of SSR240600C versus placebo on clinical and cystometric parameters in patients with OAB and UUI.</brief_summary>
	<brief_title>MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.</brief_title>
	<detailed_description>Prospective, randomized, parallel group, double-dummy, placebo and active-controlled (Detrol LA - tolterodine) trial wherein patients with OAB or UUI will receive single daily does of either SSR240600C 500 mg, tolterodine 4 mg or placebo for four weeks. Baseline and end of study cystometry will be performed; daily symptom diaries will be completed during the trial and health-related quality of life will be measured before and after study drug treatment. Patients will be followed-up one week after completion of the trial. Study participation will include 5 visits over a period of six weeks.</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Urinary Incontinence, Urge</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>Females between 18 and 75 years, inclusive Clinical diagnosis of OAB/UUI (symptoms of frequent micturition, urinary urgency) Bladder capacity &lt;/= 300 mL by cystometry History of interstitial cystitis, bladder outlet obstruction or other significant genitourinary disorder Current urinary tract infection Neurological bladder dysfunction Treatment with drugs that may interfere with CYP3A4 metabolic function History of stress urinary incontinence</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Cystometry NK1 Antagonist SSR240600C</keyword>
</DOC>